drugset / Trial / NCT07212998

Plasma Resuscitation Early for Evaluating Volume and Endotheliopathy of Thermal Injury (PREEVEnT) Trial

NCT07212998

Phase 3 Not yet recruiting 750 enrolled Jason Sperry United States Department of Defense · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

The Plasma Resuscitation Early for Evaluating Volume and Endotheliopathy of Thermal Injury (PREEVEnT) trial will be a 5-year (3-year enrollment), open label, phase-3, multi-center, early in-hospital phase randomized trial utilizing burn centers from within the LITES network and will enroll approximately 750 injured adult patients who have suffered large 2nd or 3rd degree thermal burns on at least 20% of their body surface requiring burn resuscitation. The objective is to determine if initiating plasma resuscitation as soon as possible upon arrival to an emergency department or burn unit is the most effective resuscitation for those who have experienced large thermal burns and significantly reduces the morbidity and mortality attributable to post-injury complications as compared to standard in-hospital resuscitation practice.

Timeline

Start
2026-08
Primary completion
2029-08
Completion
2029-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Plasma Other / unclassified

Indications

No indication recorded.